scispace - formally typeset
D

Daisuke Mikami

Researcher at University of Fukui

Publications -  34
Citations -  459

Daisuke Mikami is an academic researcher from University of Fukui. The author has contributed to research in topics: Kidney & Podocalyxin. The author has an hindex of 10, co-authored 32 publications receiving 297 citations.

Papers
More filters
Journal ArticleDOI

Short-chain fatty acids, GPR41 and GPR43 ligands, inhibit TNF-α-induced MCP-1 expression by modulating p38 and JNK signaling pathways in human renal cortical epithelial cells.

TL;DR: Investigating whether SCFAs activate GPR41 and GPR43, and thereby exert anti-inflammatory effects in human renal cortical epithelial cells (HRCEs) as a main component of kidney tissue suggested that SCFA modification may be a new therapeutic tool for preventing progression of renal inflammation and fibrosis.
Journal ArticleDOI

A short-chain fatty acid, propionate, enhances the cytotoxic effect of cisplatin by modulating GPR41 signaling pathways in HepG2 cells

TL;DR: The data suggest that a combination of propionate with cisplatin may have better therapeutic effects on HCC compared with conventional treatment, and that a selective GPR41 agonist may be a candidate as an adjuvant therapeutic agent for HCC.
Journal ArticleDOI

Cloning of rabbit alpha(1b)-adrenoceptor and pharmacological comparison of alpha(1a)-, alpha(1b)- and alpha(1d)-adrenoceptors in rabbit.

TL;DR: A high identity of structural and pharmacological profiles of three distinct alpha(1)-adrenoceptor subtypes between rabbit and other species is indicated, but there are species differences in their distribution.
Journal ArticleDOI

Telmisartan activates endogenous peroxisome proliferator-activated receptor-δ and may have anti-fibrotic effects in human mesangial cells.

TL;DR: It is indicated that in HMC telmisartan activates endogenous PPAR-δ and may prevent TGF-β1-induced fibrotic changes by reducing ERK phosphorylation in a PPARδ-dependent manner, and thus, might be useful for treating hypertensive patients with renal and metabolic disorders.
Journal ArticleDOI

β-Hydroxybutyrate enhances the cytotoxic effect of cisplatin via the inhibition of HDAC/survivin axis in human hepatocellular carcinoma cells.

TL;DR: Investigating whether βOHB enhances cisplatin-induced apoptosis in hepatocellular carcinoma (HCC) cells by modulating activity and/or expression of HDACs found it to be a new adjuvant agent for cisPlatin chemotherapy.